CN101134054A - Pharmaceutical composition for improving urination disorders caused by BPH and method for making the same - Google Patents
Pharmaceutical composition for improving urination disorders caused by BPH and method for making the same Download PDFInfo
- Publication number
- CN101134054A CN101134054A CNA2006101260016A CN200610126001A CN101134054A CN 101134054 A CN101134054 A CN 101134054A CN A2006101260016 A CNA2006101260016 A CN A2006101260016A CN 200610126001 A CN200610126001 A CN 200610126001A CN 101134054 A CN101134054 A CN 101134054A
- Authority
- CN
- China
- Prior art keywords
- extract
- semen ginkgo
- pharmaceutical composition
- panacis quinquefolii
- radix panacis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses one kind of medicine composition prepared with ginseng or American ginseng, ginkgo and other isogenous medicine and food botanic materials and through extraction in alcohol solution or water, concentration of the extract, drying and other steps. The medicine composition can eliminate BPH caused urinary dysfunction, and has no toxicity and less side effects. It may be used in preparing medicine and health food for eliminating BPH caused urinary dysfunction.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that improves the dysuria that benign prostate hyperplasia (BPH) causes that can be used in, it can be used as medicine and health food uses.
The invention still further relates to two kinds of preparation methoies of dysuria pharmaceutical composition due to the above-mentioned BPH of improvement.
Background technology
The dysuria that benign prostate hyperplasia (BPH) causes is the common frdquently encountered disease of a kind of harm and puzzlement middle-aging male health, and particularly in recent years along with the increase of aging population, its sickness rate constantly rises.With the U.S. is example, almost has U.S.'s adult male of 1/3 to suffer from benign prostate hyperplasia according to statistics.In China, the benign prostate hyperplasia sickness rate also has the trend that increases rapidly, according to investigations more than 41 years old the sickness rate of Chinese male from 1936 6.6% rise to present 30.5%.
Modern medicine is used to improve that the medicine of dysuria mainly contains two kinds due to the BPH, and a kind of is α
1-adrenergic receptor blocker, another is plant amedica such as Pollen Preparations:
α
1-adrenergic receptor blocker mainly acts on the smooth muscle of prostate and neck of bladder, reduces its tension force, thereby removes the kinetic factor that bladder outlet is obstructed, and makes clinical symptom remission or elimination, and it represents medicine for breathing out pleasure, terazosin etc.To improve the BPH dysuria evident in efficacy for quick for this class medicine, but the patient has side effect in various degree after taking.
Clinically be used to improve BPH plant amedica commonly used Cefasabal and Pollen Preparations Prostat, QIANLIEKANG etc. are arranged, the advantage of this class medicine is a safety, but slow curative effect usually, prompt effect is relatively poor.
The dysuria that BPH causes belongs to difficulty in urination category in Chinese medicine.The traditional Chinese medical science difficulty in urination refers to dysuria, and the urine line is thin and delicate, and urine is inaccessible obstructed.It is not smooth to urinate, the frequent micturition urine thin, and the slow person of patient's condition is infirmity; Desire separate, the urine drop is obstructed, little distention and fullness in the abdomen, and the more anxious person of patient's condition is for closing.The mechanism of compound Chinese medicinal preparation (as LONGBISHU etc.) treatment BPH is many target spots, multi-faceted treatment, its advantage is that the patient is carried out the integral body conditioning, safety, its shortcoming is same as the plant amedica in the modern medicine, particularly improving aspect the dysuria substantially all barely satisfactoryly fast, all be difficult to make the patient to feel that dysuria is obviously alleviated after normally taking medicine 20～30 days.
Summary of the invention
In order to overcome the deficiencies in the prior art, the object of the present invention is to provide a kind of pharmaceutical composition that can effectively improve dysuria due to the BPH, its component is the plant of dietotherapeutic.The characteristics of this pharmaceutical composition are prescription simple (having only two flavor medicines), and curative effect is obvious, safety, and prompt effect is strong, takes usually effectively to change the subjective and objective Signs of BPH patient after 3～5 days, takes the immunologic function and the defying age that also can strengthen the patient for a long time.
Another object of the present invention provides that above-mentioned can to improve the dysuria that BPH causes be two kinds of preparation methoies of the pharmaceutical composition of main effect.
In order to finish purpose of the present invention, the following technical scheme of special proposition.
The present invention is that its feature system is made by the raw material of following weight parts with Radix Ginseng (or Radix Panacis Quinquefolii) and Semen Ginkgo two flavor medical material prescriptions:
Radix Ginseng 1 weight portion (or Radix Panacis Quinquefolii 0.5 weight portion) Semen Ginkgo 1～3 weight portion
This medicine is preferably the medicament of being made by the raw material of following weight parts:
Radix Ginseng 1 weight portion (or Radix Panacis Quinquefolii 0.5 weight portion) Semen Ginkgo 2 weight portions
In other words, the present invention relates to a kind of pharmaceutical composition, it is characterized in that it is the medicament of being made by the following weight proportion raw material: the weight proportion that the people participates in Semen Ginkgo is 1: 1～1: 3, is preferably 1: 2, or the weight proportion of Radix Panacis Quinquefolii and Semen Ginkgo is 0.5: 1～0.5: 3, is preferably 0.5: 2.
The invention still further relates to a kind of drug extract that can improve dysuria due to the BPH, this extract adopts following method to obtain:
1) the broken back of 1 weight portion Radix Ginseng (or 0.5 weight portion Radix Panacis Quinquefolii) is boiled with alcoholic solution or decocting, through the chromatography purification, drying gets Radix Ginseng (or Radix Panacis Quinquefolii) extract;
2) water after 1～3 weight portion Semen Ginkgo fragmentation is decocted, filter, concentrate, drying gets Semen Ginkgo extract;
3) Radix Ginseng (or Radix Panacis Quinquefolii) extract and Semen Ginkgo extract are mixed pulverizing, sieve, be extract of the present invention.
By raw materials used Radix Ginseng 1 weight portion (or Radix Panacis Quinquefolii 0.5 weight portion), Semen Ginkgo 2 weight portions of being preferably of the drug extract of method for preparing.That is, the weight proportion of employed Radix Ginseng of this drug extract and Semen Ginkgo is 1: 1～1: 3, is preferably 1: 2, or the weight proportion of Radix Panacis Quinquefolii and Semen Ginkgo 0.5: 1～0.5: 3, is preferably 0.5: 2.
In order to finish purpose of the present invention, can also directly mix pulverizing with the Semen Ginkgo water extract with Radix Ginseng (or Radix Panacis Quinquefolii) extract that contains the different purity ginsenoside, its weight proportion, can be according to ginsenoside's content, according to the weight proportion of foregoing Radix Ginseng (or Radix Panacis Quinquefolii) with the Semen Ginkgo prescription, actual extracting rate in conjunction with them is calculated, for example: content of ginsenoside is 30% Radix Ginseng (or Radix Panacis Quinquefolii) extract (extraction ratio is 5%), the weight proportion of itself and Semen Ginkgo water extract (extraction ratio is 7%) should be 1: 1.4～4.2 (1: 2.8～8.4), its optimum ratio is 1: 2.8 (1: 5.6), by that analogy.
Therefore, the present invention relates to a kind of pharmaceutical composition, it is characterized in that it is that 30% Radix Ginseng or Radix Panacis Quinquefolii extract and Semen Ginkgo water extract are formed by content of ginsenoside, wherein content of ginsenoside is that 30% the Radix Ginseng extract and the weight proportion of Semen Ginkgo water extract are 1: 1.4～1: 4.2, or content of ginsenoside is that 30% the Radix Panacis Quinquefolii extract and the weight ratio of Semen Ginkgo water extract are 1: 2.8～1: 8.4.
Above-described pharmaceutical composition and drug extract contain acceptable carrier or additive on the materia medica, can be processed as said dosage form on any pharmaceutics.
In addition, the invention still further relates to two kinds and prepare that can to improve the dysuria that BPH causes be the method for the drug extract of main effect, this method may further comprise the steps:
Method one
1) 1 weight portion Radix Ginseng (or 0.5 weight portion Radix Panacis Quinquefolii) is boiled with alcoholic solution or decocting, through the chromatography purification, drying gets Radix Ginseng (or Radix Panacis Quinquefolii) extract;
2) 1～3 weight portion Semen Ginkgo water is decocted, filter, concentrate, drying gets Semen Ginkgo extract;
3) Radix Ginseng (or Radix Panacis Quinquefolii) extract is mixed pulverizing with Semen Ginkgo extract, sieve and promptly get extract of the present invention.Promptly wherein the weight proportion of Radix Ginseng and Semen Ginkgo is 1: 1～1: 3, is preferably 1: 2; The weight proportion of Radix Panacis Quinquefolii and Semen Ginkgo is 0.5: 1～0.5: 3, is preferably 0.5: 2.
Method two
1 weight portion Radix Ginseng (or 0.5 weight portion Radix Panacis Quinquefolii), 1～3 weight portion Semen Ginkgo fragmentation are together boiled (or taking the ultrasonic circulating method to extract) with alcoholic solution or decocting, filter, concentrate, drying is pulverized, and sieves, and gets extract of the present invention.That is, wherein the weight proportion of Radix Ginseng and Semen Ginkgo is 1: 1～1: 3, is preferably 1: 2, or the weight proportion of Radix Panacis Quinquefolii and Semen Ginkgo is 0.5: 1～0.5: 3, is preferably 0.5: 2.
In other words, as well known to those skilled in the art, can adopt known method to extract various raw materials of the present invention respectively, make dry extract separately respectively, carry out dried, crushing screening, mixed then the mixture that contains various raw extracts of the present invention.
The invention further relates to described pharmaceutical composition or extract and can be used for making health food or food supplement.
The dysuria that pharmaceutical composition of the present invention or extract conduct can improvement BPH cause is the medicine of main effect; have anti-senescence function concurrently; can be used for heart tonifying, protecting myocardial cell and increase myocardial nutritional flow amount, both took for a long time and can improve dysuria, again can building body.Pharmaceutical composition of the present invention or extract have following characteristic and advantage:
1. pharmaceutical composition of the present invention or the selected raw material of extract all are medicated diet homology food plant, and each component meets People's Republic of China's " health food management method " and Medicine Act regulation, nontoxic (pair) effect, and people can take for a long time.
2. pharmaceutical composition of the present invention or extract are improving aspect the dysuria that BPH causes, effect is more obvious, and prompt effect is stronger, takes usually and can tentatively improve the subjective and objective Signs of BPH patient after 3～5 days.
3. pharmaceutical composition of the present invention or extract not only can effectively improve outside the dysuria that BPH causes through human body and animal experiment proof, and have found out the major function factor (ginsenoside) content and the mechanism of action.
4. pharmaceutical composition of the present invention or extract need not to decoct, and be easy to carry and use, meets People's Republic of China's health legislation regulation.
5. pharmaceutical composition of the present invention or extract have the potential value of the series of products of being developed further into (food, health food, medicine).
The range of application of pharmaceutical composition of the present invention or extract:
1. this product can be used as food, the health food of dysuria, defying age and the raise immunity improving BPH and cause.
2. this product can be used as the medicine that improves the dysuria that BPH causes.
Description of drawings
Accompanying drawing 1 is the technological process 1 of the inventive method.
Accompanying drawing 2 is the technological process 2 of the inventive method.
The specific embodiment
Further specify the present invention below with reference to accompanying drawing 1, accompanying drawing 2 and embodiment.
Embodiment 1
Referring to accompanying drawing 1,27 kilograms of Radix Ginsengs (meeting Pharmacopoeia of the People's Republic of China regulation) are broken with the decoction of 70% alcoholic solution, and through the chromatography purification, drying gets 1.35 kilograms of extracts; 54 kilograms of Semen Ginkgo fragmentations are decocted with water, filter, concentrate, drying gets 3.78 kg of water and promotes extractum; Extract and water that above-mentioned steps obtains are promoted extractum mixing pulverizing, cross 80 mesh sieves, get extract of the present invention.
Embodiment 2
Repeat the step of embodiment 1, different is that Radix Ginseng changes Radix Panacis Quinquefolii (meeting Pharmacopoeia of the People's Republic of China regulation) into, consumption changes 13.5 kilograms into, Semen Ginkgo still is 54 kilograms, other operating procedure is identical with embodiment 1, get 0.68 kilogram of Radix Panacis Quinquefolii extract (wherein content of ginsenoside is 30%) and 3.78 kilograms of Semen Ginkgo dry extracts, it is mixed pulverize.
Embodiment 3
Referring to accompanying drawing 2, select for use 9 kilograms Radix Ginseng (or 4.5 kilograms of Radix Panacis Quinquefoliis) and 18 kilograms broken respectively the aqueous solution of Semen Ginkgo to decoct jointly with 8 times of amounts, after boiling, first pass decocted 1 hour, filter, leave standstill; Decocted 45 minutes after boiling for second time, filter, leave standstill; Twice decocting liquid mixed, cryoconcentration, spray drying gets extract of the present invention.
Embodiment 4
27 kilograms of Radix Ginsengs (or 13.5 kilograms of Radix Panacis Quinquefoliis) and 54 kilograms of Semen Ginkgoes are mixed micronizing to 500 order, get pharmaceutical composition of the present invention.
1 embodiment one week of 1 administration of experimental example is to improving the urodynamic influence of prostatic hyperplasia rat model due to the testosterone propionate
1.1 test material
1.1.1 animal:
The SD rat, secondary, male, (100 ± 10) g is provided by animal science portion of the Capital University of Medical Sciences, the quality certification number: SCXK (capital) 2000-0012
1.1.2 medicine:
Embodiment 1, provides lot number by Europe, Beijing nail (unit of length) bio tech ltd: 050415;
Paracetamol (QIANLIEKANG): Kang Enbei Zhejiang Pharmaceutical Co, lot number: 050524;
Terazosin: Hainan Lutao pharmaceutical Co. Ltd, lot number: 20030121.
1.1.3 reagent:
Testosterone propionate, Shanghai General Pharmaceutical Co., ltd. produces, lot number: 030701
1.2 dosage design:
According to preparation prescription, working out clinical people's consumption is 3.0g/1d/ people.Be converted into rat and be equivalent to 0.3g/kg, according to pre-test result, embodiment 1 large, medium and small three dosage are made as 3.0,1.5,0.75g/kg, are equivalent to isodose 10 times, 5 times, 2.5 times of clinical humans; Paracetamol is made as 2.5g/kg, is equivalent to isodose 5 times of clinical human.
1.3 test method and result
1.3.1 method:
List of references
[1]Method, the SD rat, male, body weight 100 ± 10g, random packet, 10～12 every group: 1. sham operated rats (normal saline 5ml*kg
-1, PO) 2. model control group (normal saline 5ml*1Kg
-1, PO) 3. model+positive controls (paracetamol 2.5g*kg
-1, PO, 1 week of administration) 4. model+embodiment 1 small dose group (0.75g*kg
-1, PO, 1 week of administration) 5. dosage group (1.5g*kg among model+embodiment 1
-1, PO, 1 week of administration) the 6. heavy dose of group of model+embodiment 1 (3.0g*kg
-1, 1 week of PO administration), other establishes one group model+terazosin hydrochloride group (2mg/kg, PO test administration in preceding 1 hour).
Except that sham operated rats, all experimental animals are in the operation of the descending castration of aseptic condition, and in one week of postoperative, experimental animal subcutaneous injection respectively is dissolved in the testosterone propionate 0.5mg*0.1ml of olive oil
-1* Mus
-1, continuous 4 weeks; Last 1 week test medication embodiment 1 and positive drug paracetamol respectively in experiment, 1 day 1 time, continuous 1 week.Sham operated rats is only taken out testis, puts back to scrotum again, do not excise, every day orally give normal saline 0.5ml.
Experimental animal behind 1h after the last administration according to document
[3,4]Method is carried out the rat urodynamics and is measured, record urinate threshold pressure, urinate maximumly press, urine journey (double urinating blanking time), once urine amount (ml), residual urine amount (ml).
Statistical procedures: experimental data represents that with X ± SD experimental result is carried out variance analysis with the SPSS11.5 statistical software.
1.3.2 result:
1.3.2.1 embodiment 1 week of 1 administration is to the urodynamic influence of prostatic hyperplasia rat model due to the testosterone propionate
Every day, gastric infusion was 1 time, 1 week of successive administration, compare with model control group, and the threshold pressure of urinating of embodiment 1 each dosage group, terazosin hydrochloride group, paracetamol group rat obviously descends, and significant difference is remarkable.Embodiment 1 each dosage group, terazosin hydrochloride group rat urinate blanking time (s) obviously prolongs, and significant difference is remarkable.The once urine amount of embodiment 1 big or middle dosage group rat obviously increases, and significant difference is remarkable; The residual urine amount of heavy dose of group, terazosin hydrochloride group rat obviously reduces, and significant difference is remarkable.The results are shown in following table.
Embodiment 1 week of 1 administration is to the urodynamic influence of prostatic hyperplasia rat model due to the testosterone propionate
(X±SD，n＝10)
| Group | Dosage (g/kg) | The threshold pressure (kpa) of urinating | Maximum press (kpa) urinates | (s) urinates blanking time | Urine amount (ml) once | Residual urine amount (ml) |
| Sham operated rats | 10.7±1.5 | 38.7±3.3 | 123.4±34.1 | 0.52±0.17 | 0.35±0.14 | |
| Model+ | ||||||
| The normal saline group | — | 21.2±2.2 ## | 31.9±4.7 # | 19.3±12.8 ## | 0.19±0.07 ## | 1.15±0.77 ## |
| Embodiment 1 heavy dose of group | 30 | 11.7±2.6 ** | 35.9±6.9 | 120.3±52.6 ** | 0.45±0.26 ** | 0.44±0.21 * |
| Dosage group among the embodiment 1 | 15 | 12.8±2.1 ** | 33.6±6.0 | 103.5±34.6 ** | 0.40±0.13 * | 089±0.64 |
| Embodiment 1 small dose group | 0.75 | 14.1±2.9 ** | 31.4±3.4 | 65.5±22.6 ** | 0.33±0.15 | 091±0.62 |
| The paracetamol group | 2.5 | 15.6±2.2 ** | 32.9±4.7 | 16.3±5.2 | 0.26±0.13 | 0.75±0.68 |
| Terazosin hydrochloride | 0.002 | 15.5±2.4 ** | 33.4±5.59 | 57.1±14.83 ** | 0.24±0.15 | 0.50±0.22 * |
Compare with sham operated rats:
#: P＜0.05;
##: P＜0.01
Compare with model normal saline matched group:
*: P＜0.05;
*: P＜0.01
The Radix Ginseng extract of experimental example 2 embodiment 2, embodiment 4, content of ginsenoside 30% respectively one week of administration to improving the urodynamic influence of prostatic hyperplasia rat model due to the testosterone propionate
2.1 test material
2.1.1 animal:
The SD rat, secondary, male, (100-200g), provide the quality certification number: SCXK (capital) 2002-0001 by animal science portion of the Capital University of Medical Sciences
2.1.2 medicine:
Testosterone propionate Shanghai General Pharmaceutical Co., ltd. lot number: 030701
Chlormadinone Hubei KeYi Pharmacentic Co., Ltd. lot number: 040303
Terazosin: Hainan Lutao pharmaceutical Co. Ltd lot number: 20030121
Embodiment 2, Europe, Beijing nail (unit of length) bio tech ltd lot number: 041011;
Embodiment 4, Europe, Beijing nail (unit of length) bio tech ltd lot number: 041012;
Radix Ginseng extract: the grand bio tech ltd of a specified duration in Radix Ginseng total saponins 〉=30% (HPLC) Jilin Province
Lot number: 040515-T;
2.2 test method
2.2.1 modelling:
The method of list of references, 53 ST rats, male, pentobarbital sodium 60*kg
-1Ip anesthesia, in the descending castration operation of aseptic condition, in one week of postoperative, subcutaneous injection is dissolved in the testosterone propionate 0.5mg*0.1ml of olive oil
-1* Mus
-1, to give simultaneously and chlormadinone, continuous use 30 days carries out urodynamics next day and measures and take by weighing each lateral lobe weight in wet base of prostate; Began respectively in the 24th day to terazosin, embodiment 2, embodiment 4, Radix Ginseng extract, continuous use 7 days, the last administration was carried out urodynamics in 3 hours and is measured.
2.2.2 grouping:
1. sham operated rats (normal saline 5ml*1kg
-1, PO) 2. model control group (normal saline 5ml*1kg
-1, PO) 3. positive 1 matched group (chlormadinone 50 μ g*1kg
-1, PO) 4. positive 2 matched groups (terazosin 1ml*kg
-1, PO) 5. embodiment 2 (3.0g/kg, PO) 6. embodiment 4 (5.0g/kg, PO) 7. Radix Ginseng extract (0.4g/kg, PO)
2.2.3 the mensuration of rat lot number intravesical pressure:
The method of list of references, ST rat, lumbar injection chloral hydrate (0.3mg*kg
-1PO) anesthesia, superior margin of pubic symphysis longitudinal incision 2cm otch, expose bladder, in hole of thorn, bladder top, two lumen catheter are inserted bladder, fix with No. 4 silk threads, outer tube (diameter 1.2mm) links to each other with the BL410 system with record intravesical pressure, interior pipe (diameter 0.61mm) (the rate of flooding 0.5ml*min that links to each other with syringe pump by YH-4
-1), wherein interior pipe is than outer pipe range 2mm.
2.3 result
Embodiment 2, embodiment 4, Radix Ginseng extract are to the urodynamic influence of prostatic hyperplasia rat (n=10)
| Group | Dosage | The urodynamics parameter | |||
| Urine journey (s) | Urine amount (ml) | Residual urine amount (ml) | Intravesical pressure (mmHg) | ||
| Sham operated rats | 5.0ml/kg | 119.68±0.13 | 0.23±0.14 | 0.15±0.15 | 32.77±9.65 |
| Model group | 5.0ml/kg | 25.78±7.04 | 0.06±0.07 | 0.64±0.38 | 34.01±8.87 |
| The chlormadinone group | 5.0μg/kg | 162.05±77.81 ** | 0.21±0.14 ** | 0.31±0.27 * | 29.42±4.42 |
| The terazosin group | 1.0mg/kg | 134.65±64.22 ** | 0.16±0.10 * | 0.48±0.39 | 27.71±3.67 * |
| Embodiment 2 | 3.0g/kg | 157.32±100.59 ** | 0.18±0.11 * | 0.19±0.13 ** | 29.58±4.56 |
| Embodiment 4 | 5.0g/kg | 88.15±37.24 | 0.13±0.07 | 0.52±0.30 | 31.35±2.81 |
| Radix Ginseng extract | 0.4g/kg | 40.25±9.01 | 0.08±0.05 | 0.59±0.21 | 32.05±7.63 |
Compare with model group:
*P＜0.05;
*P＜0.01
2.4 conclusion
The urodynamics of 2 pairs of prostatic hyperplasia rats of embodiment has the improvement effect, and wherein to the urine journey, residual urine amount is improved obviously, and it has compared significant difference with model group; Though the urodynamics of 4 pairs of prostatic hyperplasia rats of embodiment has improvement, efficacy effect is not obvious; Content of ginsenoside is 30% Radix Ginseng extract not to be had to improve to the urodynamics of prostatic hyperplasia rat substantially.
Claims (25)
1. pharmaceutical composition, it is characterized in that it is the medicament of being made by the following weight proportion raw material: the weight proportion that the people participates in Semen Ginkgo is 1: 1～1: 3, or the weight proportion of Radix Panacis Quinquefolii and Semen Ginkgo is 0.5: 1～0.5: 3.
2. pharmaceutical composition according to claim 1, wherein the people to participate in the weight proportion of Semen Ginkgo be 1: 2, or the weight proportion of Radix Panacis Quinquefolii and Semen Ginkgo is 0.5: 2.
3. pharmaceutical composition according to claim 1 wherein, further contains acceptable carrier on the materia medica in the described pharmaceutical composition.
4. can improve the application in the dysuria medicine due to the BPH according to the arbitrary described pharmaceutical composition of claim 1～3 in preparation.
5. according to the purposes of the arbitrary described pharmaceutical composition of claim 1～3 in preparation food or health food.
6. according to the arbitrary described pharmaceutical composition of claim 1～3, wherein the said composition grinding and processing is become powder, capsule and tablet.
7. drug extract is characterized in that this extract obtains through following method:
1) with boiling with alcoholic solution or decocting after Radix Ginseng or the Radix Panacis Quinquefolii fragmentation, through the chromatography purification, drying gets Radix Ginseng or Radix Panacis Quinquefolii extract;
2) water after the Semen Ginkgo fragmentation is decocted, filter, concentrate, drying gets Semen Ginkgo extract;
3) Radix Ginseng or Radix Panacis Quinquefolii extract are mixed pulverizing with Semen Ginkgo extract, sieve.
8. drug extract according to claim 7, wherein, the weight proportion of Radix Ginseng and Semen Ginkgo is 1: 1～1: 3, or the weight proportion of Radix Panacis Quinquefolii and Semen Ginkgo 0.5: 1～0.5: 3.
9. drug extract according to claim 8, wherein, the weight proportion of Radix Ginseng and Semen Ginkgo is 1: 2, or the weight proportion of Radix Panacis Quinquefolii and Semen Ginkgo is 0.5: 2.
10. drug extract according to claim 7 wherein, further contains the carrier of accepting on the materia medica in the described extract.
11., wherein, described drug extract is processed into the dosage form of accepting on any pharmaceutics according to the arbitrary described drug extract of claim 7～10.
12. can improve the application in the dysuria medicine due to the BPH in preparation according to the arbitrary described drug extract of claim 7～10.
13. according to the purposes of the arbitrary described drug extract of claim 7～10 in preparation food or health food.
14. pharmaceutical composition, it is characterized in that it is that 30% Radix Ginseng or Radix Panacis Quinquefolii extract and Semen Ginkgo water extract are formed by content of ginsenoside, wherein content of ginsenoside is that 30% the Radix Ginseng extract and the weight proportion of Semen Ginkgo water extract are 1: 1.4～1: 4.2, or content of ginsenoside is that 30% the Radix Panacis Quinquefolii extract and the weight ratio of Semen Ginkgo water extract are 1: 2.8～1: 8.4.
15. pharmaceutical composition according to claim 14, wherein content of ginsenoside is that 30% the Radix Ginseng extract and the weight proportion of Semen Ginkgo water extract are 1: 2.8, or content of ginsenoside is that 30% the Radix Panacis Quinquefolii extract and the weight ratio of Semen Ginkgo extract are 1: 5.6.
16. pharmaceutical composition according to claim 14, wherein said pharmaceutical composition further contains acceptable carrier on the materia medica.
17. can improve the application in the dysuria medicine due to the BPH in preparation according to the arbitrary described pharmaceutical composition of claim 14～16.
18. according to the purposes of the arbitrary described pharmaceutical composition of claim 14～16 in preparation food or health food.
19., wherein, described pharmaceutical composition is processed into the dosage form of accepting on any pharmaceutics according to the arbitrary described pharmaceutical composition of claim 14～16.
20. a method for preparing the described drug extract of claim 7 is characterized in that:
1) Radix Ginseng or Radix Panacis Quinquefolii are boiled with alcoholic solution or decocting, through the chromatography purification, drying gets Radix Ginseng
Or Radix Panacis Quinquefolii extract;
2) the Semen Ginkgo water is decocted, filter, concentrate, drying gets extract;
3) Radix Ginseng or Radix Panacis Quinquefolii extract are mixed pulverizing with Semen Ginkgo extract, sieve.
21. method according to claim 20, wherein the people to participate in the weight ratio of Semen Ginkgo be 1: 1～1: 3, or the weight ratio of Radix Panacis Quinquefolii and Semen Ginkgo is 0.5: 1～0.5: 3.
22. method according to claim 21, wherein the people to participate in the weight ratio of Semen Ginkgo be 1: 2, or the weight ratio of Radix Panacis Quinquefolii and Semen Ginkgo is 0.5: 2.
23. a method for preparing the described drug extract of claim 7 is characterized in that: boil (or taking the ultrasonic circulating method to extract) with alcoholic solution or decocting with Radix Ginseng or Radix Panacis Quinquefolii, Semen Ginkgo are broken together, filter, concentrate, drying is pulverized and is got final product.
24. method according to claim 23, wherein the people to participate in the weight ratio of Semen Ginkgo be 1: 1～1: 3, or the weight ratio of Radix Panacis Quinquefolii and Semen Ginkgo is 0.5: 1～0.5: 3.
25. method according to claim 24, wherein the people to participate in the weight ratio of Semen Ginkgo be 1: 2, or the weight ratio of Radix Panacis Quinquefolii and Semen Ginkgo is 0.5: 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101260016A CN101134054A (en) | 2006-08-30 | 2006-08-30 | Pharmaceutical composition for improving urination disorders caused by BPH and method for making the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101260016A CN101134054A (en) | 2006-08-30 | 2006-08-30 | Pharmaceutical composition for improving urination disorders caused by BPH and method for making the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101134054A true CN101134054A (en) | 2008-03-05 |
Family
ID=39158506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101260016A Pending CN101134054A (en) | 2006-08-30 | 2006-08-30 | Pharmaceutical composition for improving urination disorders caused by BPH and method for making the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101134054A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018500285A (en) * | 2014-10-31 | 2018-01-11 | 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ | Composition for prevention and treatment of benign prostatic hyperplasia containing carrot seed oil |
-
2006
- 2006-08-30 CN CNA2006101260016A patent/CN101134054A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018500285A (en) * | 2014-10-31 | 2018-01-11 | 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ | Composition for prevention and treatment of benign prostatic hyperplasia containing carrot seed oil |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102727586B (en) | Composition for preventing and treating diabetes | |
| CN102724991B (en) | Traditional Chinese medicine composition for treating oral ulcer and tumor, preparation method and use thereof | |
| CN100998650A (en) | Use of cinnamonum cassia for treating diabetes, its products and preparing method | |
| CN101797301B (en) | Medicine for preventing and curing middle and old aged constipation | |
| CN101822704A (en) | Drug combination for removing freckles and preparation method thereof | |
| CN103860941A (en) | Traditional Chinese medicine for treating schizophrenia and preparation method thereof | |
| CN104147394B (en) | A kind of dendrobium candidum compound preparation and preparation method thereof | |
| CN1329049C (en) | Blood sugar- and blood pressure-lowering medicine | |
| CN107050351A (en) | A kind of Chinese medicine composition relaxed bowel and preparation method and application | |
| CN100548363C (en) | Medicine of treatment benign prostate hyperplasia and preparation method thereof | |
| CN100509012C (en) | Medicine for treating postoperative gastroenteropathy | |
| CN101134054A (en) | Pharmaceutical composition for improving urination disorders caused by BPH and method for making the same | |
| CN103566312B (en) | Traditional Chinese medicine combination for treating loss of appetite of pigs | |
| CN105664053A (en) | Traditional Chinese medicine composition for treating calluses on puncture of internal arteriovenous fistula of maintenance hemodialysis patient | |
| KR100542898B1 (en) | Extracts derived from Chinese medicines for preventive measures and the incontinence of urine and manufacturing thereof | |
| CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
| CN105853766A (en) | Purpose of traditional Chinese medicinal preparation for preparing medicine for treating primary hypertension | |
| CN106617038B (en) | Health food composition for improving male frequent micturition and urinary incontinence and preparation method and application thereof | |
| CN101269137B (en) | Traditional Chinese medicine composition for treating hemorrhoid | |
| CN105055851A (en) | Chinese medicinal composition for treatment of diabetes, preparation and application thereof | |
| CN101450162A (en) | Traditional Chinese medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN104815140A (en) | Composition for preventing or/and treating diabetes and preparation method of composition | |
| CN104258224A (en) | Schisandra chinensis oral solution for treating lung-and-kidney yin-deficiency type chronic bronchitis and preparation method thereof | |
| CN107854612A (en) | A kind of medicine for treating constipation and preparation method thereof | |
| CN107648522A (en) | A kind of pharmaceutical composition for treating constipation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20080305 |